Ratings Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Real-time Estimate Cboe BZX Other stock markets 01:47:10 2024-05-28 pm EDT			5-day change	1st Jan Change
12.52 ^USD	-1.69%		-13.98%	-30.70%

May. 14	Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	MT
May. 14	Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PLIANT THERAPEUTICS, INC.	-29.71%	768M	C-
ELI LILLY AND COMPANY	+38.51%	727B	C+
NOVO NORDISK A/S	+31.93%	594B	B
JOHNSON & JOHNSON	-6.23%	354B	C+
MERCK & CO., INC.	+18.78%	328B	B-
ABBVIE INC.	+1.35%	277B	C+
ASTRAZENECA PLC	+14.80%	243B	B+
NOVARTIS AG	+7.69%	205B	B-
ROCHE HOLDING AG	-6.05%	203B	A+
AMGEN INC.	+6.19%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes